Vivus, Inc. (VVUS): Earnings Preview

The VIVUS earnings report coming on Monday could be a harsh reality check about the long-term prospects for Qsymia. More 

Orexigen (OREX) Stock Shoots Higher as Contrave Goes on Sale

Orexigen's Contrave joined a couple other FDA-approved weight-loss treatments on the market ... and the OREX product is a serious player. More 

20 Cheap Stocks Under $10 Worth Zilch

Cheap stocks under $10 are tempting because of their low share price, but some picks are cheap for a reason. Avoid these "bargain" stocks! More 

Mannkind (MNKD) – Right Stock, Wrong Time

Ten years' worth of work from Mannkind Corporation on Afrezza has just been validated, but that doesn't automatically make the stock a good bet right here, and right now. More 

VVUS: Vivus Stock Soars on Buyout Buzz

VIVUS shares rose sharply in Wednesday trading after regulatory filings revealed that an investment fund is considering making a $640 million bid for VVUS. More 

VVUS: VIVUS Stock Drops Following Piper Jaffray Downgrade

VIVUS stock (VVUS) has taken a hit following a downgrade by equities research analysts at Piper Jaffray. More 

Bad Day for VIVUS: Why VVUS Stock Is Tumbling

Shares of VIVUS fell sharply in Tuesday trading after the company posted a smaller quarterly loss as investors worried about the sales of its Qsymia drug. More